RxDoctor Payments Data

John Cefalu, MD

Interventional Pain Medicine · Shreveport, LANPI 1659804979

Payments from drug & device makers

What this record shows

This record is dominated by grants: $50,000 of the $70,739 with a category attached, or 70.7%. 26 manufacturers reported payments, led by Boston Scientific at 56.6% of the total. Reporting peaked in 2021 at $51,709 and has fallen 94.4% since, to $2,879 in 2025. Among interventional pain medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$70,739in general payments, 2019–2025

Across 338 payments — averaging $209.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$40K
  • Medtronic$22K
  • Relievant Medsystems, Inc.$1K
  • Vertos Medical, Inc.$936
  • Surgentec$809
  • Interventional Pain Technologies Inc.$781
  • plus $4K from 20 others

What the payments were for

  • Grants$50,00071%
  • Travel & lodging$7,68911%
  • Food & beverage$12,98618%
  • Education$640%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,739 in reported general payments places this provider in the 95th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$316,701
Medicare patients
230
Services billed
8,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen341$6,498
Buprenorphine12$3,789
Gabapentin233$2,275
Pregabalin125$1,691
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen59$1,221
Tizanidine Hcl80$829
Mupirocin87$740
Tramadol Hcl62$629
Diclofenac Sodium18$363
Meloxicam120$328
Cephalexin87$266
Duloxetine Hcl28$254
Celecoxib11$215
Methylprednisolone12$101
Oxycodone Hcl11$77

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →